What is Periphagen?
Periphagen operates at the intersection of advanced biotechnology and neurology, utilizing its proprietary Neuronal Therapeutics (NET) platform to address the unmet needs of patients suffering from chronic pain and neuropathy. By employing herpes simplex virus type I (HSV-1) as a sophisticated gene therapy vector, the company achieves targeted gene expression within sensory neurons, effectively mitigating the systemic side effects often associated with traditional pharmacological interventions. With over two decades of operational experience, Periphagen has transitioned from a research-focused entity into a critical infrastructure provider, offering specialized HSV-1 manufacturing services that have supported multiple human clinical trials. This dual-track business model—combining internal drug development with high-value manufacturing capabilities—positions the company as a versatile player in the gene therapy landscape, capable of scaling its operations to meet the rigorous demands of modern clinical medicine.
How much funding has Periphagen raised?
Periphagen has raised a total of $6.5M across 1 funding round:
Private Equity
$6.5M
Private Equity (2014): $6.5M, investors not publicly disclosed
Key Investors in Periphagen
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Periphagen?
The infusion of capital is expected to accelerate the maturation of Periphagen's pipeline, particularly as the company seeks to expand the application of its NET platform beyond peripheral nerve disorders. Strategic priorities likely include the optimization of its manufacturing facilities to support larger-scale clinical trials and the potential licensing of its vector technology to external partners. As the biopharmaceutical industry shifts toward more precise, localized therapeutic delivery, Periphagen is well-positioned to capitalize on the growing demand for non-systemic, gene-based treatments. Future growth will be defined by the company's ability to navigate the regulatory landscape while maintaining its competitive edge in HSV-1 vector engineering and clinical execution.
See full Periphagen company page
